logo
Plus   Neg
Share
Email

CRISPR Therapeutics (CRSP) Is Climbing After FDA Clinical Hold Lifted

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) announced after the bell Wednesday that the FDA has lifted the clinical hold on CTX001 and has accepted the Investigational New Drug application for the drug.

CRISPR Therapeutics traded in a range for the majority of Wednesday's session and closed down by 0.21 at $36.64. The stock is rising 4.26 on 58K shares after the bell.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT